Objective: Evaluation of In-vivo therapeutic effects of Clopidogrel 75mg (Lowplat) given once daily for seven days to the patients requiring antiplatelet therapy. Methodology: This is an open label, multicenter study to determine the platelet aggregation inhibition of the study drug in adult subjects suffering from diseases requiring antiplatelet therapy i.e. coronary artery diseases (CAD), per...

BACKGROUND Numerous trials have reported on the morning increase in the occurrence of myocardial infarction, stroke and sudden cardiac death. Similarly, enhanced morning platelet aggregation has been observed in healthy individuals and in subjects with coronary artery disease without adequate antiplatelet treatment. The purpose of the study was to assess circadian variation in platelet aggregat...

BACKGROUND Antiplatelet therapy has proven beneficial in the treatment of cardiovascular disease. Proton pump inhibitors (PPIs) are commonly used for gastroprotection in patients receiving antiplatelet therapy. Several trials have been carried out to establish interactions between PPIs, clopidogrel and soluble formulations of aspirin, but no studies with PPIs and enteric-coated (EC) forms of as...

Studies have shown that adjunctive cilostazol to dual ntiplatelet therapy in patients undergoing percutaneous oronary intervention (PCI) may decrease late restenosis nd enhance inhibition of adenosine diphosphate (ADP)nduced platelet aggregation, providing a rationale for triple ntiplatelet therapy (3–5). The appealing hypothesis that riple antiplatelet therapy may provide more profound latelet...

BACKGROUND AND PURPOSE Antiplatelet therapy nonresponse is associated with worse clinical outcomes. We studied the clinical outcomes associated with platelet function-guided modifications in antiplatelet therapy in patients with ischemic stroke or transient ischemic attack. METHODS From January 2005 to August 2007, 324 patients with ischemic stroke underwent platelet function testing using pl...

BACKGROUND Although the impact of tranexamic acid on platelet function remains controversial, tranexamic acid is part of clinical algorithms for the management of platelet dysfunction. The goal of our prospective, observational study was to examine the effects of tranexamic acid on platelet function in patients treated with dual antiplatelet therapy compared to those who ceased antiplatelet the...

BACKGROUND Aspirin is a cornerstone in management of coronary artery disease (CAD). However, considerable variability in the antiplatelet effect of aspirin has been reported. AIM To investigate independent determinants of reduced antiplatelet effect of aspirin in stable CAD patients. METHODS We performed a cross-sectional study including 900 stable, high-risk CAD patients. Among these, 795 ...

Aim To study the antiplatelet aggregation of ticlopidine (TC). Methods Using coronary artery Folts model in beagles, the efficacy of TC on platelet aggregation was studied. Results (1)TC16, 32 mg•kg -1 dramatically inhibited the frequency of CFRs dose-dependently, and the times of CFRs decreased by 27%, 56%, 95%, 100% respectively at 1-4 h than that in control group’s after TC 32 mg•kg -1 admin...

Background Antiplatelet agents, such as aspirin and P2Y12 inhibitors, are essential in the secondary prevention of cardiovascular disease [1]. Despite effective treatment with these drugs, many patients still suffer ischemic events. This suggests the need for additional antiplatelet therapy. The P2Y1 receptor is a seven transmembrane G protein coupled receptor responsible for platelet shape cha...

Background Antiplatelet agents, such as aspirin and P2Y12 inhibitors, are essential in the secondary prevention of cardiovascular disease [1]. Despite effective treatment with these drugs, many patients still suffer ischemic events. This suggests the need for additional antiplatelet therapy. The P2Y1 receptor is a seven transmembrane G protein coupled receptor responsible for platelet shape cha...